More than 732,000 bottles were included in a 2025 recall described in a new federal complaint. The lawsuit alleges that purchasers paid for a heart drug contaminated by a nitrosamine and made without adequate quality controls.
InvestigationTL;DR
- A federal complaint says the Food and Drug Administration announced a nationwide recall of more than 732,000 bottles of Glenmark carvedilol in March 2025, followed by additional recalls that August.
- The filing says the recalled drug contained N-Nitroso-Carvedilol I, a nitrosamine impurity, and that Glenmark attributed the problem to inadequate control of nitrite levels in ingredients used to make the tablets.
- Named plaintiff Sharon Carroll says she paid for Glenmark carvedilol on four occasions and would have chosen another product—or at the very least paid less monies for it—had the contamination and alleged manufacturing failures been disclosed.
- The proposed class seeks economic damages such as purchase and replacement costs. It expressly does not seek damages for physical injuries, although the complaint alleges unwanted exposure and possible future health consequences.
- The complaint connects the recalls to broader quality-control problems, including FDA warning letters to Glenmark’s corporate affiliate. It concedes, however, that redactions prevent it from showing that every warning-letter observation concerned carvedilol.
The recalls are documented in the complaint; the lawsuit’s much broader claim (specifically that a common manufacturing defect affected Glenmark’s carvedilol beyond the recalled lots) remains unproven.
Transparency notice: This article relies on the class-action complaint filed by Sharon Carroll and on regulatory records, company statements, scientific guidance, and warning-letter language quoted or described within that complaint. A complaint is an advocate’s account, not a judicial finding. The supplied record contains no answer from Glenmark, no class-certification order, no merits ruling, and no independent copies of the cited FDA records. The proposed class and its allegations therefore remain untested.
The Facts
Carvedilol is a beta-blocker used to treat high blood pressure, heart failure, and related cardiac conditions. According to the complaint, the FDA approved the branded drug Coreg in 1995 and authorized Glenmark to sell a generic version in September 2007.
That generic status carries a practical promise: the product is supposed to match the approved drug in identity, strength, quality, purity, safety, and therapeutic effect. It must also be manufactured under current Good Manufacturing Practices, or cGMPs—the minimum systems required to control ingredients, processes, laboratory testing, records, and finished-drug quality.
The complaint says that promise broke down in 2025. It cites FDA recall records covering more than 732,000 bottles of Glenmark carvedilol in March and further recalls in August. The stated problem was a nitrosamine impurity identified as N-Nitroso-Carvedilol I, together with alleged manufacturing-practice deviations.
Carroll identifies purchases on March 16 and October 4, 2024, and March 31 and July 2, 2025. The prescriptions carried National Drug Codes 68462-0164-05 and 68462-0163-05. An NDC identifies the manufacturer or labeler, formulation, strength, and package configuration; it is not the same as a lot number, which identifies a particular production batch.
The lawsuit alleges that Carroll’s tablets were contaminated because they carried the same NDCs, and were within their expiration periods at the same time, as products later tested and recalled. That is the plaintiff’s inference. The complaint does not provide a test result from Carroll’s own pills.
How the Impurity Allegedly Formed
Nitrosamines can form when certain amines encounter nitrite under suitable manufacturing or storage conditions. The complaint says carvedilol’s chemical structure was vulnerable to that reaction and quotes Glenmark as attributing the contamination to a failure to control nitrite levels in excipients—the inactive ingredients used to produce a finished tablet.
This diagram summarizes the mechanism alleged in the complaint. It is not a judicial finding about every batch or lot.
The distinction between a process impurity and an isolated contaminant drives much of the lawsuit. A one-time foreign contaminant may affect a limited batch. A process impurity can recur whenever the same ingredients and conditions are used. On that basis, the plaintiff alleges that the defect extended beyond the lots formally recalled.
That conclusion remains disputed territory. The complaint does not provide batch-by-batch measurements, the concentration found in each recalled lot, or testing from every lot sold. It alleges that reported levels exceeded an acceptable intake limit, but it does not supply the numerical results needed to calculate an individual purchaser’s exposure or risk.
A recall covering hundreds of thousands of bottles does not establish that every bottle reached a patient—or that every Glenmark carvedilol lot contained the same amount of impurity.
Who Paid—and What the Recall Meant
The complaint’s central damages claim is economic. Patients paid copayments or other out-of-pocket costs, while insurers and other third-party payors reimbursed pharmacies. Those transactions were processed using the NDC attached to the dispensed drug.
Carroll says she would not have paid for Glenmark’s product, would have paid less, or would have sought another carvedilol manufacturer had she known of the alleged contamination and quality-control failures. The proposed nationwide class would include individuals and entities that paid any amount for Glenmark carvedilol intended for personal or household use. A Washington subclass is also proposed.
The exact number of purchasers is not established. The complaint says the proposed class exceeds 100 members and may include hundreds of entities, but a bottle count cannot be converted into a patient count. Bottles may contain different quantities, remain in inventory, be returned, or never be dispensed.
For recalled inventory, the immediate practical consequence was removal from use. The complaint quotes Glenmark’s recall communication as telling pharmacy, wholesale, and retail customers to quarantine the affected product and stop dispensing it.
What the source says
“Quarantine such product immediately and not dispense any further.” Glenmark recall instruction as quoted in the complaint, paragraph 134
The impurity “may be associated with a potential increased cancer risk in humans.” Glenmark recall language as quoted in the complaint, paragraph 134
The lawsuit does not seek compensation for diagnosed cancer or another physical injury. It alleges unwanted exposure to a substance with mutagenic properties and refers to possible future health consequences, but it seeks recovery for the money paid, replacement medication, unusable recalled product, and related economic losses. The supplied record establishes no diagnosis, individual dose, or causal link between Glenmark carvedilol and illness in Carroll or any proposed class member.
Warnings, Quality Controls, and the 2025 Recalls
The complaint argues that Glenmark should have been alert to nitrosamine formation years before its recall. It cites scientific literature dating back decades, international guidance describing nitrosamines as a high-priority class of mutagenic carcinogens, and the wave of nitrosamine-related drug recalls that began in 2018.
General scientific knowledge, however, is not the same as proof that Glenmark knew its own carvedilol was contaminated. The filing alleges both actual and constructive knowledge—meaning knowledge the company had, or should have obtained through proper testing and oversight. The supplied material does not establish when Glenmark first received a positive carvedilol test.
According to the complaint, the FDA approved Coreg, the branded carvedilol product.
Glenmark received approval to sell its generic carvedilol, the complaint says.
Large recalls involving nitrosamines in other medicines brought industry-wide attention to the issue. The complaint cites FDA advice directing manufacturers to assess nitrosamine risks.
An FDA warning letter cited significant cGMP violations at a Glenmark affiliate’s facility. The complaint does not establish that the redacted products discussed were carvedilol.
The FDA inspected Glenmark’s Pithampur facility in India, according to the complaint.
The complaint says the FDA announced a nationwide recall covering more than 732,000 bottles of Glenmark carvedilol.
A further FDA warning letter cited testing, investigation, stability, and laboratory-control deficiencies at Pithampur.
Additional Glenmark carvedilol recalls were announced for nitrosamine contamination, according to the filing.
Carroll filed the proposed class action.
The warning letters matter because the cited deficiencies involve the systems that should detect manufacturing problems: investigation of failed batches, written production controls, stability testing, scientifically sound laboratory methods, and complete records. Yet the complaint itself acknowledges a critical limit. Product names in the warning letters were redacted, so those observations may be evidence of broader quality-system weaknesses without proving a carvedilol-specific violation.
What the Evidence Supports—and What It Doesn’t
| Evidence described | What it supports | What remains unproven |
|---|---|---|
| FDA recall records cited for March and August 2025 | The complaint’s account that identified Glenmark carvedilol lots were recalled over nitrosamine contamination and manufacturing-practice concerns. | That every bottle or every lot Glenmark sold was contaminated at the same level. |
| Glenmark statements quoted in the filing | The company attributed the impurity to inadequate nitrite control in excipients and instructed customers to quarantine recalled product. | When Glenmark first knew of positive results and whether it had previously conducted adequate risk assessments. |
| 2022 and 2025 FDA warning-letter language | Regulators identified significant cGMP deficiencies within Glenmark’s corporate manufacturing network. | Whether each cited deficiency involved carvedilol or caused the recalled impurity. |
| Carroll’s purchase dates and NDCs | She alleges that she paid for Glenmark-labeled carvedilol during the period at issue. | A laboratory result for her pills or confirmation that her specific lot was recalled. |
| Scientific and regulatory guidance | Nitrosamine formation was a known pharmaceutical-manufacturing risk requiring assessment and control. | Specific knowledge, intent, fraud, and the contamination level of products outside tested or recalled lots. |
Glenmark’s Response in the Available Record
No litigation response from Glenmark was supplied. The company’s position is represented only through statements that the complaint attributes to its recall communications.
Those statements acknowledged nitrosamine impurities as the reason for the market withdrawal, warned of a potential increase in cancer risk, directed supply-chain customers to quarantine the product, and attributed the contamination to uncontrolled nitrite levels in excipients. The record provided here does not show whether Glenmark accepts the plaintiff’s larger claims about every batch, the value of the drug, its prior knowledge, or its legal liability.
The Legal Fight
Carroll’s complaint pleads nine causes of action: breach of express warranty, breach of implied warranty, violation of the federal Magnuson-Moss Warranty Act, fraud, negligent misrepresentation, violations of state consumer-protection laws, negligence, negligence per se, and unjust enrichment.
The theory underneath those counts is straightforward. Purchasers allegedly paid for an FDA-approved generic equivalent manufactured under required quality systems. The plaintiff says they instead received a product containing an undisclosed impurity and therefore worth nothing—or at least less than the price paid.
The complaint seeks certification of a nationwide class and state subclasses, refunds and replacement costs, restitution, punitive or exemplary damages where available, statutory penalties, an injunction, interest, and legal fees. Requested relief is not awarded relief.
What the court has actually decided
Nothing on the merits appears in the supplied record. Filing a complaint does not certify a class, establish contamination beyond recalled or tested lots, prove fraud, or entitle purchasers to repayment. Glenmark has not been found liable, and the court has not decided whether Carroll can represent other purchasers.
What Remains Unresolved
- Scope: Which lots tested positive, at what concentrations, and how closely did those lots overlap with the named plaintiff’s purchases?
- Timing: When did Glenmark first identify a carvedilol-specific nitrosamine risk or receive a positive result?
- Manufacturing link: Which facilities made the recalled products, and did the FDA warning-letter observations directly concern carvedilol?
- Class-wide proof: Can common records show who paid for the affected products and distinguish recalled lots from other Glenmark carvedilol?
- Economic loss: Were purchasers entitled to the full purchase price, a smaller price premium, replacement costs, or no class-wide damages?
- Health consequences: The complaint alleges exposure and possible future risk but supplies no individual dose assessment, diagnosis, or proven physical injury.
The source document for this investigation is attached below.
Related posts:
They Needed Preservative-Free Eye Drops. Allergan Sold Them a Lie.
Gilead Shelved a Safer HIV Drug to Protect Patent Profits. California’s Top Court Just Ruled That’s Not Its Problem.
Frontida BioPharm Caught Storing Toxic Waste Without a Permit | Adare Pharma Solutions
Bayer Sold Fake Fertility Promises to Desperate Fathers
